Oncogenomics
Genomic solutions to change how cancer will be identified and treated
Benefit of NGS in Oncology
- As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.
- Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
- This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.
- NGS has the potential to change the future of oncology and advance the promise of personalized medicine.
Enabling flexible, scalable comprehensive genomic profiling from FFPE samples
- Analyze multiple variant types and key biomarkers in 500+ genes across DNA and RNA in a single assay
- Go from sample to results in 4-5 days using manual or automated workflows that integrate library prep, sequencing, and data analysis
- Generate accurate data and reliable results that meet demanding performance specifications
- Keep samples in house and obtain data that is relevant to the local institution and community
Analyze multiple tumor types and biomarkers with a single workflow
- TruSight Oncology 500 are next-generation sequencing (NGS) assays that simultaneously analyze both DNA and RNA in one integrated workflow. Panel content includes multiple variant types and key bio- markers across 523 cancer-relevant genes for DNA and RNA, eliminating the need to spend time and precious sample, such as formalin fixed, paraffin embedded (FFPE) tissue blocks, on iterative testing.
Benefit of NGS in Oncology
As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.
Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.
NGS has the potential to change the future of oncology and advance the promise of personalized medicine.
Enabling flexible, scalable comprehensive genomic profiling from FFPE samples
Analyze multiple variant types and key biomarkers in 500+ genes across DNA and RNA in a single assay
Go from sample to results in 4-5 days using manual or automated workflows that integrate library prep, sequencing, and data analysis
Generate accurate data and reliable results that meet demanding performance specifications
Keep samples in house and obtain data that is relevant to the local institution and community
Analyze multiple tumor types and biomarkers with a single workflow
TruSight Oncology 500 are next-generation sequencing (NGS) assays that simultaneously analyze both DNA and RNA in one integrated workflow. Panel content includes multiple variant types and key bio- markers across 523 cancer-relevant genes for DNA and RNA, eliminating the need to spend time and precious sample, such as formalin fixed, paraffin embedded (FFPE) tissue blocks, on iterative testing.